Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study to Test Whether BI 771716 Helps People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy
NCT06722157 · View on ClinicalTrials.gov ↗
Study Summary
This study is open to people 50 years or older with an eye condition called geographic atrophy. The purpose of this study is to compare a medicine called BI 771716 with a medicine called pegcetacoplan. BI 771716 is being developed to treat people with geographic atrophy. Pegcetacoplan is a medicine already used to treat people with geographic atrophy. In this study, participants receive either BI 771716 or pegcetacoplan as injections in the eye. Participants are in the study for a little longer than a year and visit the study site every 4 weeks. At the visits, the study doctor checks the eyes of the participants. The results are compared between the groups of participants to see whether the treatment works. The study doctor also regularly checks participants' health and takes note of any unwanted effects.
Conditions Studied
Interventions
- DRUG Pegcetacoplan
- DRUG BI 771716
- DRUG Sham comparator to BI 771716
Study Locations (20)
California
- Global Research Management — Glendale
- Retina Associates of Southern California — Huntington Beach
- Retinal Consultants Medical Group, Inc — Modesto
- Eye Research Foundation — Newport Beach
- Retina Consultants of San Diego — Poway
- Retinal Consultants Medical Group — Sacramento
- Bay Area Retina Associates - Walnut Creek — Walnut Creek
Arizona
- Associated Retina Consultants — Gilbert
- Associated Retina Consultants, Ltd. — Phoenix
- Phoenix Retina Associates — Phoenix
- Retina Macula Institute of Arizona — Scottsdale
Florida
- Rand Eye Institute — Deerfield Beach
- Retina Group of Florida — Fort Lauderdale
- Eye Associates of Pinellas — Pinellas Park
- Retina Vitreous Associates of Florida — St. Petersburg
Connecticut
- Connecticut Eye Consultants, PC — Danbury
- Retina Group of New England, PC — Waterford
Colorado
- Colorado Retina Associates — Lakewood
Georgia
- Southeast Retina Center, PC — Augusta
Illinois
- University Retina and Macula Associates — Lemont
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 202 participants |
| Start Date | 2025-01-06 |
| Est. Completion | 2026-10-16 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06722157
The ClinicalTrials.gov registry entry for NCT06722157 describes a study currently listed as active not recruiting. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 202 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 203 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 2 conditions, with Geographic Atrophy appearing as the primary indexed condition, and to 3 interventions — of which Pegcetacoplan is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06722157 reports 20 study locations spanning 7 distinct geographic areas — top geographies include California, Arizona, Florida. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06722157 about?
NCT06722157 is a clinical study titled "A Study to Test Whether BI 771716 Helps People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy". This study is open to people 50 years or older with an eye condition called geographic atrophy. The purpose of this study is to compare a medicine called BI 771716 with a medicine called pegcetacoplan. BI 771716 is being developed to treat people with geographic atrophy. Pegcetacoplan is a medicine ...
What is the current status of trial NCT06722157?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 202 participants. The study started on 2025-01-06. Estimated completion is 2026-10-16.
What conditions does trial NCT06722157 study?
This clinical trial studies the following conditions: Geographic Atrophy, Macular Degeneration, Age-related. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06722157?
The interventions under investigation include: Pegcetacoplan (DRUG), BI 771716 (DRUG), Sham comparator to BI 771716 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06722157?
This trial is sponsored by Boehringer Ingelheim, which has 203 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06722157 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.